Stabilizing the cold plasma-stimulated medium by regulating medium’s composition by Yan, Dayun et al.
Himmelfarb Health Sciences Library, The George Washington University
Health Sciences Research Commons
Biochemistry and Molecular Medicine Faculty
Publications Biochemistry and Molecular Medicine
5-2016










See next page for additional authors
Follow this and additional works at: http://hsrc.himmelfarb.gwu.edu/smhs_biochem_facpubs
Part of the Biomedical Engineering and Bioengineering Commons, and the Molecular Biology
Commons
This Journal Article is brought to you for free and open access by the Biochemistry and Molecular Medicine at Health Sciences Research Commons. It
has been accepted for inclusion in Biochemistry and Molecular Medicine Faculty Publications by an authorized administrator of Health Sciences
Research Commons. For more information, please contact hsrc@gwu.edu.
APA Citation
Yan, D., Nourmohammadi, N., Bian, K., Murad, F., Sherman, J. H., & Keidar, M. (2016). Stabilizing the cold plasma-stimulated
medium by regulating medium’s composition. Scientific Reports, 6 (). http://dx.doi.org/10.1038/srep26016
Authors
Dayun Yan, Niki Nourmohammadi, Ka Bian, Ferid Murad, Jonathan H. Sherman, and Michael Keidar
This journal article is available at Health Sciences Research Commons: http://hsrc.himmelfarb.gwu.edu/smhs_biochem_facpubs/
205
1Scientific RepoRts | 6:26016 | DOI: 10.1038/srep26016
www.nature.com/scientificreports
Stabilizing the cold plasma-
stimulated medium by regulating 
medium’s composition
Dayun Yan1, Niki Nourmohammadi2, Ka Bian3, Ferid Murad3, Jonathan H. Sherman4 & 
Michael Keidar1
Over past several years, the cold plasma-stimulated medium (PSM) has shown its remarkable 
anti-cancer capacity in par with the direct cold plasma irradiation on cancer cells or tumor tissues. 
Independent of the cold plasma device, PSM has noticeable advantage of being a flexible platform in 
cancer treatment. Currently, the largest disadvantage of PSM is its degradation during the storage over 
a wide temperature range. So far, to stabilize PSM, it must be remained frozen at −80 °C. In this study, 
we first reveal that the degradation of PSM is mainly due to the reaction between the reactive species 
and specific amino acids; mainly cysteine and methionine in medium. Based on this finding, both H2O2 
in PSM and the anti-cancer capacity of PSM can be significantly stabilized during the storage at 8 °C 
and −25 °C for at least 3 days by using phosphate-buffered saline (PBS) and cysteine/methionine-
free Dulbecco’s Modified Eagle Medium (DMEM). In addition, we demonstrate that adding a tyrosine 
derivative, 3-Nitro-L-tyrosine, into DMEM can mitigate the degradation of PSM at 8 °C during 3 days of 
storage. This study provides a solid foundation for the future anti-cancer application of PSM.
Over the past decade, cold atmospheric plasma has shown a selective anti-cancer capacity both in vitro1–8 and 
in vivo9–13. Various type of cold plasma devices were used to directly irradiate cancer cells cultured in the 
multi-well plates4,14, petri-dishes1,15, or tumor tissues9,12. Recently, plasma-stimulated medium (PSM) proved to 
exhibit a significant anti-cancer capacity as strong as the direct cold plasma treatment on glioblastoma cells16–18, 
lung carcinoma cells19, and bladder cancer cells20. Very recently, it is reported that microsecond-pulsed 
plasma-activated media is able to selectively inhibit the growth of lung cancer (H460) cells rather than normal 
lung cancer (L132) cells21. Another very recent study about the selective apoptosis in the PSM treated glioblas-
toma cells22, further confirming that PSM is a selective anti-cancer tool. The injection of PSM into mice also 
significantly inhibits the growth of tumor23. Thus, PSM may have wide application in cancer treatment including 
specific situations where cold atmospheric plasma cannot reach deep seated tumors or when the cold plasma 
device is not portable.
The cold plasma-originated reactive species are thought to be the main factor in cancer cell death and growth 
inhibition24. In fact, the feasibility of using PSM to kill cancer cells is a direct evidence to support this conclusion. 
When cold plasma interacts with the medium both reactive oxygen species (ROS) such as hydroxyl free radicals 
(OH)25 and hydrogen peroxide (H2O2)19,26 and reactive nitrogen species (RNS) such as nitric oxide (NO)27 and 
nitrite (NO2−)17,28 are dissolved in the aqueous solution. Among them, H2O2 has been found to mainly contribute 
to the death of cancer cells after the direct cold plasma irradiation on cancer cells29–31 or the indirect cold plasma 
irradiation on the culture medium18,19.
To date, the degradation of PSM during the storage is its largest disadvantage for future clinical application. 
For pharmaceutical reasons, PSM should be stably stored for relative long time. However, as it is known PSM 
gradually loses its anti-cancer capacity during the storage at the room temperature17,19 or down to the temperature 
a few degrees above the freezing point of water19. Accordingly, the H2O2 concentration in PSM also gradually 
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decreases during the storage under these conditions19. Because the degradation of the anti-cancer capacity of PSM 
has been reported by different groups using different plasma devices and treatment doses17,19, the instability of 
PSM during the storage can be regarded as a basic feature of PSM.
So far, the sole strategy to inhibit the degradation of PSM during the storage is freeze at an adequately low 
temperature. Tetsuo Adachi et al. reported that a freeze at − 80 °C was able to stabilize the anti-cancer capacity 
of cold plasma-stimulated Dulbecco’s Modified Eagle Medium (DMEM) for a week19. However, we found that 
freezing PSM at around − 20 °C would significantly accelerate the degradation of PSM17. In fact, Tetsuo Adachi 
et al. also reported that the noticeable degradation of PSM still existed during the storage at − 30 °C19. These obser-
vations indicate that the degradation of PSM during the storage may be due to a slow temperature-dependent 
reaction which can be inhibited in an adequately cold atmosphere. Nonetheless, according to the description of 
most manufacturers of cell culture media, the ideal storage temperature range for medium is over 2 °C to 8 °C, 
rather than the freezing condition. Thus, considering the clinical application prospective, PSM at least should be 
stable at such a temperature range. So far, no method has been reported about improving the stability of PSM 
over 2 °C to 8 °C.
In this study, by comparing the H2O2 concentration in the cold plasma-stimulated phosphate-buffered saline 
(PBS) and the cold plasma-stimulated DMEM during the storage at 8 °C, 22 °C and − 25 °C, we found that the 
degradation of PSM was mainly due to the reaction between the plasma-originated reactive species and compo-
nents in DMEM. A further detailed investigation showed that cysteine and methioine were the main components 
in DMEM contributing to this process. Based on these principles, we further proved that the plasma-stimulated 
cysteine/methionine-free DMEM was much more stable than the plasma-stimulated standard DMEM during 
the storage at 8 °C, 22 °C and − 25 °C. In addition, adding a tyrosine derivative, 3-Nitro-L-tyrosine, could also 
improve the stability of cold plasma-stimulated DMEM at 8 °C but not at − 25 °C.
Results
The cold plasma device (Fig. 1a) was a typical helium cold atmospheric plasma jet generator which has been used 
in a series of studies17,18,32–34. Cold plasma jet was generated between the central electrode and the grounded ring 
electrode. The carrying gas was helium with a flow of 4.7 L/min and was controlled by a flow meter. The output 
voltage was 3.16 kV. The general research strategy is illustrated in Fig. 1b. 1 mL of PSM was made by the vertical 
irradiation on the medium in a well on a 12-well plate. Then, PSM was transferred into a 1.5 mL of centrifuge tube 
by pipette. The centrifuge tubes were stored in refrigerators with different internal temperatures (8 °C and − 25 °C) 
for 3 days. Similarly, the centrifuge tubes were stored at 22 °C when we investigated the degradation of PSM at the 
room temperature (not shown in Fig. 1b). Ultimately, PSM was either transferred to culture the seeded cancer 
cells in a 96-well plate or transferred into a black-wall 96-well plate to perform the measurement for H2O2. The 
detailed protocols for the transfer are illustrated in Methods and Fig. S1a,b. Because PBS is not suitable for cell 
culture, the protocols used to transfer the plasma-stimulated PBS is slightly different from the protocols used to 
transfer the plasma-stimulated DMEM (Fig. S1).
To understand the mechanism of PSM degradation, we first compared the H2O2 generation in the cold 
plasma-stimulated DMEM and PBS after 26 hours of storage and found that the H2O2 in plasma-stimulated PBS 
was quite stable during the storage while most H2O2 in the plasma-stimulated DMEM had been lost after 26 hours 
at 8 °C and 22 °C (Fig. 2a). The higher storage temperature for PSM, the stronger degradation occurs in PSM 
(Fig. 2a). Obviously, the instability of PSM is mainly due to the reaction between component of DMEM and 
reactive species generated by the cold plasma. Recently, we have demonstrated that the H2O2 in PSM tended to 
react with cysteine among all 20 amino acids after the plasma irradiation18. Thus, the plasma-stimulated PBS 
has higher H2O2 concentration than the plasma-stimulated DMEM (Fig. 2a). We further found that the H2O2 
concentration in the plasma-stimulated PBS was not only stable over 7 days of storage at 8 °C (Fig. 2b) but also 
stable over 3 days at − 25 °C (Fig. 2c). The stable anti-cancer capacity of the plasma-stimulated PBS over 3 days 
Figure 1. The cold plasma device (a) and the general research strategy using PSM to affect cancer cells seeded 
in multi-well plate (b).
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at 8 °C and − 25 °C was further confirmed by using the corresponding treated PBS to affect the growth of breast 
cancer (MDA-MB-231) cells (Fig. 2d). In addition, we demonstrated that the plasma-stimulated PBS could also 
effectively inhibit the growth of glioblastoma (U87MG) cells and pancreatic cancer (PA-TU-8988T) cells with a 
Figure 2. The plasma-stimulated PBS is a stable and effective anti-cancer tool. (a) The change of H2O2 
concentration in the cold plasma-stimulated DMEM and PBS during the storage at 8 °C and 22 °C for 26 hours. 
(b) The change of H2O2 concentration in the cold plasma-stimulated PBS during the storage at 8 °C for 7 days. 
(c) The change of H2O2 concentration in the cold plasma-stimulated PBS during the storage at 8 °C and − 25 °C 
for 3 days. (d) The change of anti-cancer capacity of the cold plasma-stimulated PBS during the storage at 
8 °C and − 25 °C for 3 days. (e) The effect of the cold plasma-stimulated PBS on the cell viability of U87MG, 
PA-TU-8988T, and MDA-MB-231 cells cultured in the cold plasma-stimulated PBS. (f) The change of H2O2 
concentration in 37.3 μ M H2O2-containing PBS during the storage at 8 °C for 3 days. The volume of solution for 
each well was 1 mL for all experiments. The treatment time for (a–d) was 1min and 2 min, respectively. Results 
are presented as the mean ± s.d. of three independently repeated experiments performed in triplicate (a–c,f) 
or in sextuplicate (d,e). For the cell viability, the data have been normalized to corresponding control group.
Student’s t-test was performed and the significance is indicated as ***p < 0.005.
www.nature.com/scientificreports/
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dose-dependent manner (Fig. 2e), making it a stable anti-cancer PSM over a wide temperature range. Ultimately, 
we tested whether the H2O2-containing PBS would be as stable as the cold plasma-stimulated PBS, and found 
that the H2O2-containing PBS just experienced a slight degradation over the storage at 8 °C for 3 days (Fig. 2f), 
which is similar to the slight degradation observed in the plasma-stimulated PBS (Fig. 2c). The H2O2 in PBS will 
experience a natural degradation during the storage at 8 °C. Thus, the gradual H2O2 consumption in the cold 
plasma-stimulated DMEM is due to the combined effect of the natural degradation of H2O2 in aqueous solution 
and the reaction between H2O2 and the component in DMEM. The latter mainly controls the degradation at 8 °C.
Furthermore, the effect of specific components in DMEM on the PSM degradation was comprehensively 
investigated. A comparison between DMEM and PBS reveals that 15 amino acids, glucose, calcium ion, mag-
nesium ion, and phenol red are the main composition difference between DMEM and PBS (Fig. S2). Thus, 15 
specific amino acids solutions, 1 glucose solution, 2 saline solutions (CaCl2, MgCl2), and 1 phenol red solution 
were respectively made by adding or dissolving specific component in PBS according to their concentrations 
in the standard DMEM (Fig. S3). After the plasma treatment and subsequent 26 hours of storage at 22 °C, the 
H2O2 concentrations in these solutions were measured and compared with corresponding H2O2 concentration 
in the solution just after the cold plasma treatment (Fig. 3a). The H2O2 in the plasma-stimulated PBS is quite 
Figure 3. Cysteine and methionine mainly contribute to the degradation of the plasma-stimulated DMEM 
at 22 °C and 8 °C. (a) The change of H2O2 concentration in the cold plasma-stimulated PBS containing specific 
component in DMEM during the storage at 22°C for 26 hours. (b) The change of H2O2 concentration in the 
cold plasma-stimulated cysteine/methionine-free DMEM, cysteine-free DMEM, methionine-free DMEM, and 
standard DMEM during the storage at 8 °C for 3 days. (c) The change of anti-cancer capacity of the cold plasma-
stimulated cysteine/methionine-free DMEM, cysteine-free DMEM, methionine-free DMEM, and standard 
DMEM during the storage at 8°C for 3 days. For all experiments, the volume of solution and the treatment time 
in each well was 1 mL and 1 min, respectively. Results are presented as the mean ± s.d. of three independently 
repeated experiments performed in triplicate (a,b) or in sextuplicate (c). For the cell viability, the data have been 
normalized to corresponding control group. Student’s t-test was performed and the significance is indicated as 
*p < 0.05, **p < 0.01, ***p < 0.005.
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stable over the storage. In contrast, most of the studied components cause different levels of H2O2 degradation 
in the plasma-stimulated PBS-based solution, except tryptophan, tyrosine, and lysine. Cysteine and methio-
nine cause the most significant degradation of H2O2 during the storage at room temperature. Phenylalanine 
also cause the noticeably degradation of H2O2. Based on these data, it is reasonable to predict that a modified 
DMEM without cysteine, methionine, phenylalanine or other components will be a stable PSM. So far, however, 
the modified DMEM without phenylalanine is not available on the market. Thus, we just focused on studying 
the role of cysteine and methionine on the PSM degradation. We first compared the plasma-stimulated cysteine/
methionine/glutamine-free DMEM with the plasma-stimulated arginine/lysine/glutamine-free DMEM and the 
plasma-stimulated standard DMEM and found that only the former was stable during the storage at 22 °C for 
26 hours (Fig. S4). The absence of arginine and lysine did not inhibit the H2O2 degradation in PSM (Fig. S4). 
These results are consistent with the trends revealed in Fig. 3a.
To make cysteine/methionine-free DMEM, 4 mM glutamine was added in the purchased cysteine/methio-
nine/glutamine-free DMEM. Based on these cysteine/methionine-free DMEM, we further prepared the modified 
DMEM just without cysteine and the modified DMEM just without methionine according to the description in 
Methods. Then, the specific effect of cysteine and methionine on the instability of PSM was investigated. After 
three days of storage at 8 °C, only the cold plasma-stimulated cysteine/methionine-free DMEM shows strong 
capacity inhibiting the H2O2 degradation (Fig. 3b). For cysteine and methionine, either of them will result in 
noticeable H2O2 degradation in PSM during the storage (Fig. 3b). Furthermore, the anti-cancer capacity of these 
PSM on breast cancer (MDA-MB-231) cells was investigated. In contrast to the experiments performed in the 
immediately treated medium, 3 days of storage at 8 °C causes noticeable degradation of the anti-cancer capacity 
of PSM even the modified DMEM does not contain cysteine and methionine (Fig. 3c). However, compared with 
other three cases, the cysteine/methionine-free DMEM still shows the strongest capacity to retain the effective 
species in PSM. The cysteine/methionine-free DMEM does not completely inhibit the H2O2 degradation, which 
may be due to two reasons. One is that many components other than cysteine and methionine in DMEM also 
contribute to the instability of PSM during the storage (Fig. 3a). The modified DMEM without all these reactive 
components may be as stable as PBS after the plasma irradiation. Another possibility is that some reactive species 
other than H2O2 may also contribute to the anti-cancer capacity of PSM.
Despite the optimized storage temperature for the culture medium should be between 2 °C to 8 °C, the cry-
opreservation of PSM may still be necessary at some special circumstances. For most of refrigerators served in 
pharmacies, the temperature in the freezing chamber is around − 20 °C. To date, however, PSM has been found 
even more degradable when stored at temperature around − 20 °C than that at 22 °C17 or at 4 °C19. General obser-
vation is that freezing aggravates the degradation of PSM. As we demonstrated above, both the H2O2 concen-
tration (Fig. 2c) and the anti-cancer capacity (Fig. 2d) of the cold plasma-stimulated PBS are stably retained 
during the storage at − 25 °C. Thus, the degradation of the plasma-stimulated DMEM should also be due to 
the reaction between component in DMEM and the plasma-originated reactive species such as H2O2. To verify 
this proposition, we first investigated the stability of H2O2-containing DMEM and H2O2-containing PBS under 
the freezing conditions for 3 days. It is found that, in contrast to the immediately prepared H2O2-containing 
DMEM and H2O2-containing PBS, H2O2 has been completely consumed (Fig. 4a) and has been well retained 
(Fig. 4b) in the frozen DMEM and the frozen PBS at − 25 °C, respectively. Thus, the plasma-originated or other 
sources-originated H2O2 naturally tend to strongly react with specific component in DMEM under the freezing 
conditions. In addition, similar to the trend shown in Fig. 2f, H2O2 also shows a natural tend to be slightly con-
sumed in PBS during the freezing storage. Thus, the degradation of H2O2 in PSM under the freezing condition 
is also due to the reaction between H2O2 and the components in media and a natural degradation in aqueous 
solution. The former is the main factor.
Similar to the research strategy described above, we further investigated which component in DMEM con-
tribute to the degradation of PSM during the freezing storage. This was done by comparing the degradation 
of H2O2 in 15 amino acids solutions, 1 glucose solution, 2 saline solutions (CaCl2, MgCl2), 1 phenol red solu-
tion, and PBS. These solutions were made by previously mentioned methods according to the concentration 
shown in Fig. S3. As presented in Fig. 4c, cysteine and methionine are still the two most reactive components 
in DMEM consuming the plasma-originated H2O2 during the freezing storage. Different from the trend shown 
in Fig. 3a, all studied components tend to aggravate the degradation of H2O2 in the cold plasma-stimulated PBS 
at − 25 °C, including tyrosine, tryptophan, and lysine, which in fact inhibit the degradation of H2O2 in the cold 
plasma-stimulated PBS at 8 °C (Fig. 3a). Under the freezing conditions, the H2O2 degradation in the methionine 
solution is stronger than that in the cysteine solution. Furthermore, we investigated the anti-degradation effect 
of the cysteine/methionine-free DMEM under the freezing conditions using the above mentioned methods. The 
appearance of either of cysteine and methionine in DMEM will result in the complete consumption of H2O2 after 
3 days of storage at − 25 °C (Fig. 4d). The cysteine-free DMEM is slightly more resistant to the H2O2 degradation 
than the methionine-free DMEM, which is consistent with the trend revealed in Fig. 4c that methionine is more 
reactive with H2O2 than cysteine during the freezing storage. For the cysteine/methionine-free DMEM, more 
than half of H2O2 has been consumed during the 3 days of storage at − 25 °C, which is also consisted with trend 
shown in Fig. 4c that many other components in DMEM also contribute to the instability of PSM. Ultimately, we 
compared the anti-cancer capacity of these modified DMEM on MDA-MB-231 cells. When the plasma treatment 
time is just 1 min (Fig. 4e), the difference between four experimental groups is not obvious. Such phenomenon 
may be due to the low concentration of residual H2O2 or reactive species in frozen plasma-stimulated cysteine/
methionine-free DMEM, which are too weak to cause noticeable anti-cancer effect (Fig. 4d). When the plasma 
treatment time extends to 2 min (Fig. 4e), the appearance of cysteine or methionine will significantly aggravate 
the degradation of the anti-cancer capacity of PSM. In contrast, the plasma-stimulated cysteine/methionine-free 
DMEM still causes a 60% of anti-cancer growth effect.
www.nature.com/scientificreports/
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Figure 4. Cysteine and methionine mainly contribute to the degradation of the plasma-stimulated DMEM 
under the freezing condition. (a) The change of H2O2 concentration in 34.5 μ M H2O2-containing DMEM 
during the storage at − 25 °C for 3 days. (b) The change of H2O2 concentration in 37.3 μ M H2O2-containing PBS 
during the storage at − 25 °C for 3 days. (c) The change of H2O2 concentration in the cold plasma-stimulated 
PBS containing specific component in DMEM during the storage at − 25 °C for 26 hours. (d) The change of 
H2O2 concentration in the cold plasma-stimulated cysteine/methionine-free DMEM, cysteine-free DMEM, 
methionine-free DMEM, and standard DMEM during the storage at − 25 °C for 3 days. (e) The anti-cancer 
capacity of the cold plasma-stimulated cysteine/methionine-free DMEM, cysteine-free DMEM, methionine-
free DMEM, and standard DMEM during the storage at − 25 °C for 3 days. For all experiments, the volume of 
solution in each well was 1 mL. The treatment time was 1 min for (c,d). Results are presented as the mean ± s.d. 
of three independently repeated experiments performed in triplicate (a–d) or in sextuplicate (e). For the cell 
viability, the data have been normalized to corresponding control group. Student’s t-test was performed and the 
significance is indicated as ***p < 0.005.
www.nature.com/scientificreports/
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In addition to above mentioned methods, we presented a third anti-degradation method based on 
the results shown in Fig. 3a. It is clear that tyrosine is able to slightly increase the H2O2 concentration in the 
plasma-stimulated PBS during the storage at 8 °C. Among 15 amino acids in DMEM, only tyrosine and pheny-
lalanine have aromatic ring structures (Fig. 5a). However, phenylalanine causes noticeable H2O2 degradation 
in the cold plasma-stimulated PBS during the storage at 8 °C (Fig. 3a). The only difference between tyrosine 
and phenylalanine is a hydroxyl on the aromatic ring (Fig. 5a), indicating that the modification on the aromatic 
ring of amino acids may endow the amino acids with a capacity inhibiting the degradation of H2O2 during 
the storage at 8 °C. We utilized a tyrosine derivative, 3-Nitro-L-tyrosine, which had a nitro group on the aro-
matic ring of tyrosine (Fig. 5a). 2 mM 3-Nitro-L-tyrosine-containing DMEM, 2 mM phenylalanine-containing 
DMEM, and 2 mM tyrosine-containing DMEM were prepared by dissolving purchased 3-Nitro-L-tyrosine, 
phenylalanine, and tyrosine powders in the standard DMEM, respectively. Subsequently, the stability of 
H2O2 in the plasma-stimulated DMEM, tyrosine-containing DMEM, phenylalanine-containing DMEM, and 
3-Nitro-L-tyrosine-containing DMEM stored at 8 °C were compared. 3-Nitro-L-tyrosine significantly inhibits 
the degradation of H2O2 in PSM (Fig. 5b). On the contrary, tyrosine and phenylalanine do not improve the 
stability of PSM (Fig. 5b). Furthermore, it is found that noticeable H2O2 degradation still occur in the cold 
plasma-stimulated 3-Nitro-L-tyrosine-containing DMEM and the cold plasma-stimulated standard DMEM 
after the storage at 8 °C for 3 days (Fig. 5c). Despite 60% of plasma-originated H2O2 has been lost during the 
storage, it is more effective than the plasma-stimulated standard DMEM, in which 74% of plasma-originated 
H2O2 has been lost during the 3 days of storage. Nonetheless, after the storage, the cold plasma-stimulated 
3-Nitro-L-tyrosine-containing DMEM still shows a noticeable anti-breast cancer cells capacity as strong as the 
immediately treated 3-Nitro-L-tyrosine-containing DMEM (Fig. 5d). In contrast, the anti-cancer capacity of the 
plasma-stimulated standard DMEM significantly decays during the storage (Fig. 5d).
To reveal the anti-degradation mechanism of 3-Nitro-L-tyrosine in the plasma-stimulated DMEM, we first 
investigated whether 3-Nitro-L-tyrosine was able to inhibit the H2O2 degradation in 0.2 mM cysteine-containing 
PBS, 0.2 mM methionine-containing PBS, and 0.4 mM phenylalanine-containing PBS. As shown in Fig. 5e, 
2 mM 3-Nitro-L-tyrosine is able to completely inhibit the H2O2 degradation in all three cold plasma-stimulated 
amino acids-containing PBS solutions at 22 °C. Thus, the cold plasma-stimulated DMEM may be stabi-
lized by 3-Nitro-L-tyrosine through inhibiting the reaction between some components in DMEM such as 
cysteine, methionine, or phenylalanine with the cold plasma-originated H2O2. Furthermore, we studied the 
concentration-effect of 3-Nitro-L-tyrosine on its anti-degradation effect in the plasma-stimulated DMEM. For 
the plasma-stimulated 3-Nitro-L-tyrosine-containing DMEM, the residual H2O2 after 3 days of storage increases 
as the concentration of 3-Nitro-L-tyrosine increases from 1 mM to 4 mM (Fig. 5f). After 3 days of storage at 8 °C, 
4 mM 3-Nitro-L-tyrosine-containing DMEM loses 30% of the H2O2 originated from the plasma treatment. In 
contrast, the standard DMEM loses 81% of the plasma-originated H2O2 (Fig. 5f). Finally, we identified that the 
degradation of H2O2 in the 3-Nitro-L-tyrosine-containing DMEM during the freezing storage is as extensive as 
that occurs in the standard DMEM after the plasma treatment (Fig. 5g). In short, adding 3-Nitro-L-tyrosine in 
DMEM weakens the degradation of PSM stored at 8 °C, though it cannot weaken the degradation of PSM stored 
at − 25 °C.
Discussion
Understanding the interaction between the cold atmospheric plasma and molecules in an aqueous solution builds 
the foundation of the plasma medicine. Current experimentation is mainly limited to studying chemical reactions 
between the cold plasma-originated reactive species and components in an aqueous solutions such as cell culture 
medium35. Among diverse chemicals, amino acids are not only the building blocks of all proteins involving in 
nearly all biological processes but also the main component in most cell culture media utilized in the studies 
in vitro4,6,16. The interaction between the cold plasma and the amino acids in culture media has been extensively 
investigated in past two years. A general investigation regarding the chemical modification and change of 20 
amino acids after the cold plasma treatment has been performed via high-resolution mass spectrometry35. It was 
found that hydroxylation, nitration, sulfonation, disulfide formation and sulfoxidation were the main chemical 
modification of 14 amino acids upon the cold plasma irradiation35. In addition, sulfur-containing amino acids 
such as cysteine and methionine and aromatic amino acids such as tryptophan, phenylalanine, and tyrosine were 
preferentially consumed during the plasma treatment35. It was also demonstrated that proteins in FBS consume 
the reactive species generated by cold plasma treatment significantly17. Recently, we further demonstrated that 
among 20 amino acids, cysteine was most reactive to plasma produced species including H2O218. These results 
clearly revealed that the plasma-originated reactive species will be partially consumed immediately after their 
formation in PSM. Furthermore, in this study, we proved that many components of medium particularly cysteine 
and methionine will slowly consume the plasma-originated reactive species such as H2O2 during storage. Thus, in 
designing the ideal PSM, cysteine and methionine should be avoided. Such slow reaction between reactive species 
and components in medium should be temperature-dependent, because it can be completely inhibited through 
an adequately low temperature freeze at − 80 °C19.
The discovery of the anti-degradation property of 3-Nitro-L-tyrosine provides a promising strategy to 
improve the stability of PSM because the original component of DMEM does not need to be removed. Despite 
the fact that the chemical mechanism of such anti-degradation capacity is unknown yet, adding modifications 
to the aromatic ring of tyrosine or phenylalanine may be the general strategy to obtain new derivatives capable 
to preserve H2O2 and perhaps other plasma produced reactive species. In addition, the anti-degradation effect 
of 3-Nitro-L-tyrosine first reveals that the interaction between the cold plasma and media cannot be simply 
described as the consumption of plasma-originated reactive species such as H2O2 or the modification of com-
ponent such as cysteine and methionine in the medium. Indeed, most of components in the medium tend to 
consume the plasma-originated reactive species; however, specific amino acid derivatives are able to inhibit the 
www.nature.com/scientificreports/
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Figure 5. 3-Nitro-L-tyrosine inhibits the degradation of cold plasma-stimulated DMEM. (a) Chemical 
formulas of phenylalanine, tyrosine, and 3-Nitro-L-tyrosine. (b) The change of H2O2 concentration in the 
cold plasma-stimulated standard DMEM, phenylalanine-containing DMEM, tyrosine-containing DMEM, 
and 3-Nitro-L-tyrosine-containing DMEM during the storage at 8 °C for 26 hours. (c) The change of H2O2 
concentration in the cold plasma-stimulated standard DMEM and 3-Nitro-L-tyrosine-containing DMEM 
during the storage at 8 °C for 3 days. (d) The change of anti-cancer capacity of the cold plasma-stimulated 
www.nature.com/scientificreports/
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reaction between plasma-originated reactive species and specific components in the medium such as cysteine and 
methionine. These results demonstrate that the chemical essence of interaction between cold plasma and aqueous 
solution is far from clear. We not only need to measure the immediate reaction in media due to the plasma irradi-
ation but we also have to monitor the long term dynamic reactions in PSM after the plasma irradiation.
The essence of the anti-cancer reactive species in cold plasma or PSM is still disputable. A simple comparison 
between the concentration of H2O2 (Fig. 3b) and the anti-cancer effect (Fig. 3c) in the plasma-stimulated cysteine/
methionine-free DMEM stored at 8 °C for 3 days reveals that though H2O2 just loses about 23% during the storage, 
corresponding anti-cancer capacity loses about 45% during the same storage. Perhaps other plasma-originated 
reactive species also contributes to the anti-cancer effect of PSM and decay faster than H2O2. Currently, H2O2 
has just been regarded as the main plasma-originated reactive species contributing to the anti-cancer capacity of 
cold plasma29,30. However, evidence exist that both cellular-level18,26,27 and molecular-level29,36 response of cancer 
cells to the cold plasma treatment are different from that positive control using H2O2. The cold plasma-originated 
atomic oxygen has been proven to be a main toxic reactive species to epithelial kidney cells under a specific 
plasma treatment condition37. So far, based on the accumulated data in the literature, it is premature to reach final 
conclusion regarding the mechanism of action of cold atmospheric plasma. A further comprehensive investiga-
tion on the role of key plasma-originated reactive species on the anti-cancer effect of cold plasma is necessary 
and urgent.
Conclusions
The degradation of PSM during storage is due to the reaction between the plasma-originated reactive species 
and components of the cell culture medium. We have found that cysteine and methionine are two most reactive 
components in DMEM contributing to the consumption of plasma-originated H2O2. The cold plasma-stimulated 
PBS and the cold plasma-stimulated cysteine/methionine-free DMEM can be stably stored at 8 °C and − 25 °C 
for at least 3 days. In addition, adding 3-Nitro-L-tyrosine into DMEM could weaken the degradation of the cold 
plasma-stimulated DMEM at 8 °C for 3 days. These stabilizing strategies build a solid foundation for the applica-
tion of PSM in future cancer treatment.
Methods
Medium and cell cultures. Standard Dulbecco’s modified Eagle’s medium (11965-118), the modified 
cysteine/methionine/glutamine-free DMEM (21013-024), the modified arginine/lysine/glutamine-free DMEM 
(A14431-01) and PBS (14040-133) were purchased from Gibco Life Technologies. In addition, all DMEM and 
PBS were mixed with 1% (v/v) antibiotic (penicillin and streptomycin) (Life Technologies) before any experi-
ments. Human glioblastoma (U87MG) cells and pancreatic cancer (PA-TU-8988T) cells were provided by Dr. 
Murad’s Lab at the George Washington University. Human breast cancer (MDA-MB-231) cells were provided 
by Dr. Zhang’s Lab at the George Washington University. All cancer cell lines were seeded with a confluence of 
3 × 104 cells/mL and a volume of 100 μ L in each well on 96-well plate and were cultured for 6 hours in a com-
plete media composed of Dulbecco’s modified Eagle’s medium (Life Technologies) supplemented with 10% (v/v) 
fetal bovine serum (ThermoFisher Scientific) and 1% (v/v) antibiotic (penicillin and streptomycin) solution (Life 
Technologies) under the standard cell culture conditions (a humidified, 37 °C, 5% CO2 environment). In each 
experiment, 6 wells in a single column on 96-well plate would be seeded with cancer cells.
Making plasma-stimulated PBS and DMEM. In this study, the protocols to make PSM are the same 
among different experiments. 1 mL of PBS or DMEM or other modified DMEM such as cysteine/methionine-free 
DMEM in a well on 12-well plate (Falcon) was treated by cold plasma for 1 min or 2 min. The gap between the end 
of dielectric plasma tube and the bottom of 12-well plate was 3 cm.
Making H2O2-containing PBS and DMEM. The H2O2-containing PBS and H2O2-containing DMEM 
were prepared by adding purchased 30 wt% H2O2 solution (Sigma-Aldrich) into PBS and DMEM, respectively. 
The H2O2 concentration in H2O2-containing PBS and H2O2-containing DMEM were close to the H2O2 concen-
tration in the 1 min of cold plasma-treated 1 mL of PBS or DMEM in 12-well plate, respectively.
Making the specific component-containing PBS and DMEM. The amino acids-containing PBS, the 
calcium-containing PBS, the magnesium-containing PBS, the glucose-containing PBS, the phenol red-containing 
PBS, and amino acids-containing DMEM were prepared by adding and dissolving purchased specific amino 
standard DMEM and 3-Nitro-L-tyrosine-containing DMEM during the storage at 8 °C for 3 days. (e) The  
change of H2O2 concentration in the cold plasma-stimulated single amino acids-containing PBS and double 
amino acids-containing PBS during the storage at 22 °C for 26 hours. Corresponding concentration of 
cysteine, methionine, phenylalanine, and 3-Nitro-L-tyrosine in PBS were 0.2 mM, 0.2 mM, 0.4 mM and 
2 mM, respectively. (f) The change of H2O2 concentration in the cold plasma-stimulated 3-Nitro-L-tyrosine-
containing DMEM with different concentrations during the storage at 8 °C for 3 days. (g) The change of H2O2 
concentration in the cold plasma-stimulated standard DMEM and 3-Nitro-L-tyrosine-containing DMEM 
during the storage at − 25 °C for 3 days. For all experiments, the volume of solution in each well was 1 mL. 
The treatment time was 1 min for (b,e,f) and was 2 min for (c,d,g), respectively. Results are presented as the 
mean ± s.d. of three independently repeated experiments performed in triplicate (b,c,e–g) or in sextuplicate 
(d). For the cell viability, the data have been normalized to corresponding control group. Student’s t-test was 
performed and the significance is indicated as *p < 0.05, **p < 0.01, ***p < 0.005.
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acids, calcium chloride solution, magnesium chloride solution, D-glucose and phenol red solution or amino 
acids derivative such as 3-Nitro-L-tyrosine into PBS and DMEM, respectively. Except PBS and DMEM, all above 
chemicals were purchased from Sigma-Aldrich.
Affecting the growth of cancer cells seeded in 96-well plate by the cold plasma-stimulated 
DMEM or PBS. First, the initial culture medium which has been cultured cells for 6 hours has been removed 
before this step. Then, for the plasma-stimulated DMEM (Fig. S1a), 100 μ L of treated DMEM was transferred 
from a well on 12-well plate or other tubes stored in refrigerator into a well on 96-well plate, in which 3 × 103 
cancer cells were seeded and has been cultured for 6 hours. In each experiment, 6 wells in a single column on 
96-well plate have been seeded with cancer cells. In the control group, the DMEM used to culture cancer cells 
was the untreated DMEM. For the plasma-stimulated PBS (Fig. S1b), considering that cancer cells cannot grow 
in PBS over a long time range, 100 μ L of untreated DMEM was first transferred into the well seeded with 3 × 103 
cancer cells on 96-well plate. Then, 100 μ L of treated PBS was transferred into the well which contained 100 μ L 
of untreated DMEM and 3 × 103 cancer cells. Thus, after this step, the total volume of the mixed medium in each 
well seeded with cancer cells were 200 μ L. For the control group, the PBS transferred into the well would not be 
treated. Ultimately, for above two cases, the cancer cells on 96-well plate were cultured under a standard cell cul-
ture condition (a humidified, 37 °C, 5% CO2 environment) for 3 days.
Measuring and processing the cell viability. After the experiments, the cancer cells in 96-well plates 
were cultured in 96-well plate under the standard cell culture conditions (a humidified, 37 °C, 5% CO2 environ-
ment) for 3 days. Then, according to the standard two-steps MTT measurement protocols, the viability of cancer 
cells was qualified by MTT test and was read by an H1 microplate reader (Hybrid Technology) at the absorbance 
of 570 nm. In each independent experiment, 6 wells in a single column on 96-well plate would be seeded with 
cancer cells and would be taken cell viability test. The average value of measured cell viability from 6 wells was 
regarded as the cell viability measured from one independent experiment. To facilitate the understanding on data, 
all data about cell viability shown in figures has been normalized to the control group by dividing the measured 
cell viability of experimental group by the measured cell viability of control group. The final data shown in all 
figures are the mean ± s.d. of the normalized cell viability from three independently repeated experiments.
Measuring H2O2 concentration. 50 μ L of medium or PBS which needs to be measured was transferred to 
a well on a black-wall 96-well clear bottom plate (Falcon) in triplicate. Next, according to the standard protocols 
provided by Sigma-Aldrich, the H2O2 concentration in the cold plasma-stimulated medium was measured. The 
fluorescence at 540/590 nm was read using an H1 microplate reader (Hybrid Technology).
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